Business
Ocumetics Technology Announces Closing of First Tranche of Brokered LIFE Offering Led by Centurion One Capital
(TheNewswire)     Calgary, AB – TheNewswire - January 2, 2026 – ...
About this update from Ocumetics Technology Corp
[{"type":"text","content":"Ocumetics Technology Announces Closing of First Tranche of Brokered LIFE Offering Led by Centurion One Capital\n(TheNewswire)\n\n\n \n \n\n\nCalgary, AB – TheNewswire - January 2, 2026 – Ocumetics Technology Corp. (“Ocumetics” or the\n“Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QB0) is pleased to announce that it has\nclosed the first tranche of its previously\nannounced best efforts brokered private\nplacement of units of the Company (the “Units”) for\naggregate gross proceeds of approximately $788,380 (the “Brokered\nOffering”). The Company\nis also pleased to announce the closing of a concurrent non-brokered\nprivate placement of Units for additional gross proceeds of\napproximately $235,450 (the “Non-Brokered Offering” and together with the Brokered Offering, the\n“Offerings”).\n\n\n \n\n\nThe Offerings were led by Centurion One Capital Corp.\nas lead agent and sole bookrunner (the “Lead Agent”) in\nrespect of the Brokered Offering and fiscal advisor in respect of the\nNon-Brokered Offering. Tingle Merrett LLP acted as counsel to the\nCompany, and Cassels Brock & Blackwell LLP acted as counsel to the\nLead Agent in connection with the Offerings.\n\n\n \n\n\nA total of 1,706,383 Units were\nsold under the Offerings at a price of $0.60 per Unit (the\n“Issue Price”) for aggregate gross proceeds of approximately\n$1,023,830. Each Unit consists of one common\nshare in the capital of the Company (a “Common Share”) and\none Common Share purchase warrant (a “Warrant”).  Each\nWarrant entitles the holder to purchase one additional Common Share (a\n“Warrant Share”) at a price of $0.75 until December\n30, 2028.\n\n\n \n\n\nThe gross proceeds of the Offering are expected to be\nused to fund the Corporation’s first-in-human clinical trials, for\nongoing research and development and for general corporate purposes.\n Although the Corporation intends to use the proceeds of the offering\nas described above, the actual allocation of proceeds may vary from\nthe uses set out above, depending upon future operations, events or\nopportunities.\n\n\n \n\n\nIn connection with the\nOfferings, the Company paid an aggregate of $143,...